To assess the safety and efficacy of third-line and above therapy of patients with local advanced or metastatic non-small cell lung cancer (NSCLC) with combined treatment with launched recombinant humanized anti-PD-1 monoclonal antibody and Donafenib Tosilate
Name: donafenib tablets
Description: safety assessments
Measure: safety assessments Time: From signing ICF to 30 days after the end of treatmentDescription: progression-free survival (PFS)
Measure: Effective evaluation Time: Continue treatment until the end of treatment,an average of 12 monthsAllocation: Non-Randomized
Single Group Assignment
There is one SNP
Chemotherapy treatments must include a two-drug regimen containing platinum, patients with EGFR TKI drug resistance and unknow T790M mutation, after AZD9291 treatment patients with T790M mutation could be enrolled 4, At least one measurable lesion as defined by RECIST 1.1. --- T790M ---
Chemotherapy treatments must include a two-drug regimen containing platinum, patients with EGFR TKI drug resistance and unknow T790M mutation, after AZD9291 treatment patients with T790M mutation could be enrolled 4, At least one measurable lesion as defined by RECIST 1.1. --- T790M --- --- T790M ---